Our key milestones

Our key milestones

  • 2018
    • TEOXANE


      15 year anniversary of TEOXANE: a tribute to enduring excellence

      Establishment of a new subsidiary in Poland

  • 2017
    • TEOSYAL® RHA


      9 million TEOSYAL® dermal filler injections*

      5th subsidiary in Spain after Germany, France, Italy and UK

  • 2017
    • TEOSYAL® RHA


      Opening of a second production line. FDA approval for RHA®2, RHA®3, RHA®4 for the correction of moderate to severe dynamic facial wrinkles and folds

      New packagings for HA range and new names for Redensity 1 & 2

  • 2016
    • TEOSYAL® RHA


      New cosmeceutics with RHA® technology: a serum with Vitamin C, and a hydrogel mask

  • 2015
    • TEOSYAL® RHA


      Launch of the Resilient Hyaluronic Acid gel line: TEOSYAL®RHA for Dynamic Aesthetics. A novel cross-linking technology that adapts to the movements and dynamism of the face

  • 2015
    • SKINCARE


      Cosmeceutics innovations: eye-contour and anti-ageing SPF protection

  • 2015
    • TEOSYAL® PEN


      The 1st motorised, cordless hyaluronic acid injection system - more precise injections for practitioners coupled with reduced pain for patients

  • 2014
    • TEOSYAL®


      5 million TEOSYAL® injections

  • 2014
    • TEOSYAL® RHA


      Integration of RHA resilient hyaluronic acid® , novel cross-linking HA technology, in the newly created TEOXANE Cosmeceuticals line

  • 2013
    • 10 year anniversary of TEOXANE


      Celebrating a decade of innovation, independence and the pursuit of excellence

  • 2012
    • TEOSYAL® RHA


      2 groundbreaking launches that changed anti-ageing approaches: a dermal filler, Redensity 2, specifically designed as an under- eye circle fighter and a cocktail of free HA and nutriments, Redensity 1, renown worldwide as a unique beauty booster

  • 2011
    • TEOXANE


      TEOXANE is the 3rd manufacturer to master the addition of lidocaine in dermal fillers, creating the TEOSYAL® PureSense range, for a more comfortable injection experience

  • 2009
    • TEOSYAL®


      Creation of TEOSYAL® Cosmeceuticals range – A perfect complement to facial aesthetic procedures

  • 2006
    • TEOSYAL®


      Ultra Deep, 1st volumiser by injection (fine needle)

  • 2004
    • TEOSYAL® Classic range


      A state-of-the art range of hyaluronic acid-based dermal fillers that allows practitioners to address the main rejuvenation concerns

  • 2003
    • TEOXANE


      Creation of TEOXANE Laboratories in Geneva, Switzerland

  • 2018
  • 2018
  • 2017
  • 2015
  • 2014
  • 2012
  • 2011
  • 2009
  • 2006
  • 2004
  • 2003
References

*at Teoxane Laboratories

  1. All products of the TEOSYAL® Classic, TEOSYAL® PURESENSE and TEOSYAL RHA® lines, including TEOSYAL® ULTRA DEEP, TEOSYAL KISS®, TEOSYAL PURESENSE ® REDENSITY 1 & 2, and TEOSYAL RHA® 1 to 4, are trademarks of the firm TEOXANE SA. They are class III medical devices and are regulated health products bearing the CE marking (CE0086) under this regulation. They are available in around 80 countries, excluding the US. For professional use only. Please refer to instructions for use. TEOSYAL® PURESENSE and TEOSYAL® RHA products are gels that contain hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anaesthetic can induce a positive reaction to anti-doping tests).
  2. Products of the TEOXANE Cosmeceutical range are cosmetic products according to European Regulation 1223/2009, except Radiant Night Peel which is a class I medical device, according to Directive 93/42/EEC. Cosmeceuticals products are not designed to be injected.
  3. TEOSYAL® PEN is a non-sterile class IIa medical device (CE0434) intended to assist medical practitioner for dermal filler injections. Manufactured by JuvaPlus in Switzerland. For more information, please consult the user guide of TEOSYAL® PEN or the recommendations available on www.teosyalpen.com. Please refer to instructions for use. It is the practitioner’s full responsibility to read and inform the patient about adverse reaction.
  4. RHA® is a trademark of TEOXANE SA. RHA® 2, RHA® 3, RHA® 4 are products of TEOXANE SA. They are class III medical devices and have received FDA approval but are not yet commercialized in the United States. The United States Federal law restricts these devices to sale by or on the order of a physician or license practitioner. RHA® 2, RHA® 3 and RHA® 4 are indicated for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA® 2, RHA® 3, and RHA® 4 are sterile gels containing crosslinked hyaluronic acid in physiological buffer and 0.3% lidocaine hydrochloride to reduce pain on injection. RHA® 2, RHA® 3 and RHA® 4 are contraindicated in patients with previous hypersensitivity to local anaesthetics of the amide type, such as lidocaine. Please refer to the Instructions for Use (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002C.pdf). It is the practitioner’s full responsibility to read and inform the patient about contraindications, warnings, precautions, risks and benefits.
Choose your country

Close

close
Europe

France

UK

Germany

Italy

Poland

Switzerland

International

English

close